XNAS · Healthcare · Drug Manufacturers - General
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | -0.41 | 0.00 | +100.00% | $45.1M | ✅ Beat | +1.07% | +4.27% | +1.40% |
| 2026-02-25 | Q4 2025 | -0.56 | 0.01 | +101.79% | $49.2M | ✅ Beat | +3.09% | +3.49% | +2.85% |
| 2025-10-29 |
| Q3 2025 |
| -0.03 |
| 0.19 |
| +733.33% |
| $49.7M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-30 | Q2 2025 | -0.61 | 0.04 | +106.56% | $72.7M | ✅ Beat | +1.71% | +0.53% | +0.47% |
| 2025-03-12 | Q4 2024 | -0.03 | -0.02 | +33.33% | $62.3M | ✅ Beat | +2.47% | +14.97% | +16.22% |
| 2024-10-30 | Q3 2024 | -0.05 | -0.05 | +0.00% | $42.3M | ➖ Inline | -3.74% | -1.64% | -15.86% |
| 2024-07-31 | Q2 2024 | -0.04 | 0.01 | +125.00% | $67.5M | ✅ Beat | -8.90% | -3.81% | -8.28% |
| 2024-05-01 | Q1 2024 | -0.03 | -0.01 | +66.67% | $56.5M | ✅ Beat | +9.38% | +2.81% | +3.06% |
Showing last 8 quarters.